Best Practices for 21 CFR Part 11 and GxP Validation for Electronic Records


Sponsored Content

Drug development has dramatically changed over the past ten years. Specifically when it comes to GxP compliance and validation. Many biopharma companies struggle to adopt new technologies because of the uncertainty of how to comply with FDA regulations. In this white paper, Egnyte will chronicle recent technological trends, specific challenges these trends pose for Quality & CSV teams, and best practices for tackling resulting compliance issues.

Related Content
© 2024 MJH Life Sciences

All rights reserved.